Global consensus statement on the management of pregnancy in inflammatory bowel disease
- PMID: 40876906
- DOI: 10.1136/gutjnl-2025-336402
Global consensus statement on the management of pregnancy in inflammatory bowel disease
Abstract
Background & aims: Pregnancy can be a complex and risk filled event for women with inflammatory bowel disease (IBD). High-quality studies in this population are lacking, with limited data on medications approved to treat IBD during pregnancy. For patients, limited knowledge surrounding pregnancy impacts pregnancy rates, medication adherence, and outcomes. Limited provider knowledge leads to highly varied practices in care affected by local dogma, available resources, individual interpretation of the literature, and fear of harming the fetus. The variations in guidelines by different societies and countries reflect this and lead to confusion for physicians and patients alike. The Global Consensus Consortium is a group of 39 IBD and content experts and 7 patient advocates from 6 continents who convened to review and assess current data and come to an agreement on best practices based on these data.
Methods: The GRADE process was used when sufficient published data were available and the RAND process in those instances where expert opinion was needed to guide consistent practice. Recommendations were informed by the guiding principle that maternal health best supports infant health.
Results: The topics were divided into ten categories with 34 GRADE recommendations and 35 Consensus statements.
Conclusions: Overall, the goal of the group was to provide data-driven and practical guidance to improve the care of women with IBD around the globe based on the best available research.
Keywords: GASTROSCOPY.
© Author(s) (or their employer(s)) 2025. The American Gastroenterological Association, British Society of Gastroenterology, The American College of Gastroenterology, European Crohn’s and Colitis Organisation, John Wiley & Sons Limited and Crohn’s and Colitis Foundation. Published by Elsevier Inc on behalf of The American Gastroenterological Association, by BMJ Publishing Group Ltd on behalf of British Society of Gastroenterology, by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology, by Oxford University Press on behalf of European Crohn’s and Colitis Organisation, by John Wiley & Sons Limited and by Oxford University Press on behalf of Crohn’s and Colitis Foundation. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Conflict of interest statement
Competing interests: These authors disclose the following: UM reports consultant for Abbvie, Bristol Myers Squibb, Boeringher Ingelheim, Celltrion, Enveda, Gilead, Janssen, Lilly, Merck, Pfizer, Protagonist, Roivant, and Takeda. CH. S reports advisory boards for Janssen, Abbvie, Takeda, Lilly, Ferring, Shire, Pfizer, Sandoz, Pharmascience, Fresenius Kabi, Amgen, Bristol Myers Squibb, and Celltrion; and speaker for Janssen, Abbvie, Takeda, Lilly Ferring, Shire, Pfizer, Pharmascience, and Fresenius Kabi. EL. B reports consultant for AbbVie, Boomerang, Eli Lilly, Pfizer, Takeda, and Target RWE. MC has served as speaker, consultant, or received research or education funding from MSD, Abbvie, Hospira, Pfizer, Takeda, Janssen, Ferring, Shire Pharmaceuticals, Dr Falk Pharma, Tillotts Pharma, Biogen, Gilead, and Lilly. EF reports speaker fees from Abbvie, Ferring, Janssen, Sandoz, and Takeda; and a research grant from Ferring. MJ has received research grants for other investigator-driven studies from Takeda and the NOVO Nordisk Foundation (grant no.NNF23OC0081717); has received consultation fees from Ferring and Takeda; and has received speaker’s fees from Tillotts Pharma, MSD, Ferring, and Takeda. SK reports consultant for Boerhinger Ingelheim, Bristol Meyers Squibb, Fresenius Kabi, Gilead, Janssen, Lilly, Pfizer, and Takeda; and editor for UptoDate. SN has served as an advisory board member for Pfizer, Ferring, Janssen, and Abbvie; has received honoraria as a speaker for Ferring, Tillotts, Menarini, Janssen, Abbvie, and Takeda; has received research grants through her affiliated institutions from Olympus, Ferring, and Abbvie; is a founder member, non-executive director, non-executive scientific advisor, and shareholder of GenieBiome Ltd; receives patent royalties through her affiliated institutions; and is named inventor of patent applications held by the CUHK and MagIC that cover the therapeutic and diagnostic use of microbiome. JT reports advisory board/consultancy for Abbvie, Pfizer, Sandoz, Janssen, and Lilly; speaker bureau for Abbvie, Janssen, Pfizer, and Lilly; and grants from Janssen and Abbvie. JY-F reports speaker bureau for AbbVie, Alfasigma, Asofarma, Bristol Myers Squibb, Carnot, Celltrion, Chinoin, Farmasa, Ferring, Janssen, Siegfried Rhein, and Takeda; clinical research investigator for Bristol Myers Squibb and Takeda; advisory boards for AbbVie, Celltrion, Ferring, Janssen, and Takeda; and research grants from Takeda. CR reports research grants from Abbvie; pregnancy registry for Ubrelvy; pregnancy registry Risankizumab-rzaa (Skyrizi); media editor for American Journal of Obstetrics and Gynecology; and deputy editor for American Journal of Perinatology. RG reports speaker for AbbVie, Takeda, J&J, and Celltrion; advisory boards for AbbVie, Takeda, J&J, Celltrion, and Zespri; and research grants from J&J and Zespri. DD reports lecture fees/consultancy for AbbVie, Takeda, Pfizer, Eli Lilly, Janssen, Ferring, Celltrion, and Bristol Myers Squibb. MD reports consultant for Abbvie, Abivax, Astra Zeneca, Bristol Myers Squibb, Boeringher Ingelheim, Celltrion, Genentech, Janssen, Johnson and Johnson, Lilly, Merck, Pfizer, Prometheus Labs, Spyre, and Takeda. ML reports consultant for AbbVie, BMS, Celltrion, Janssen, Intercept, Lilly, Pfizer, Prometheus, Takeda, and Target RWE; and research support from Lilly, Takeda, and Pfizer. The remaining authors disclose no conflicts.
LinkOut - more resources
Full Text Sources
